



**HAL**  
open science

## Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review

Bénédicte Sautenet, Yeoungjee Cho, Talia Gutman, Gopala Rangan, Albert Ong, Arlene B. Chapman, Curie Ahn, Helen Coolican, Juliana Tze-Wah Kao, Kevin Fowler, et al.

### ► To cite this version:

Bénédicte Sautenet, Yeoungjee Cho, Talia Gutman, Gopala Rangan, Albert Ong, et al.. Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review. *American Journal of Kidney Diseases*, 2020, 10.1053/j.ajkd.2019.12.003 . hal-03159486

**HAL Id: hal-03159486**

**<https://hal.science/hal-03159486>**

Submitted on 22 Aug 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

## **Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review**

### **Authors first and last names and highest degree:**

Bénédicte Sautenet, Ph.D.<sup>1,2</sup>, Yeoungjee Cho, M.D.<sup>3</sup>, Talia Gutman, M.Sc.<sup>4</sup>, Gopala Rangan,  
Ph.D.<sup>5</sup>, Albert Ong, Ph.D.<sup>6</sup>, Arlene B. Chapman, Ph.D.<sup>7</sup>, Curie Ahn, Ph.D.<sup>8</sup>, Helen Coolican<sup>9</sup>,  
Juliana Tze-Wah Kao, M.D.<sup>10</sup>, Kevin Fowler, Ph.D.<sup>11</sup>, Ron T. Gansevoort, Ph.D.<sup>12</sup>, Claire Geneste,  
M.D.<sup>1</sup>, Ronald D. Perrone, M.D.<sup>13</sup>, Tess Harris, patient advocate<sup>14</sup>, Vicente E. Torres, M.D.<sup>15</sup>, York  
Pei, Ph.D.<sup>16</sup>, Jonathan C. Craig, Ph.D.<sup>17</sup>, Allison Tong Ph.D.<sup>4</sup>, on behalf of the SONG-PKD  
Initiative

### **Institute of each author:**

<sup>1</sup>Service de Néphrologie-Hypertension, Dialyses, Transplantation Rénale, Hôpital de Tours, Tours,  
France

<sup>2</sup>Université de Tours, Université de Nantes, INSERM, SPHERE U1246, Tours, France

<sup>3</sup>Department of Nephrology, Princess Alexandra Hospital; Australasian Kidney Trials Network,  
University of Queensland; Translational Research Institute, Brisbane, Australia

<sup>4</sup>Sydney School of Public Health, The University of Sydney, Sydney; Centre for Kidney Research,  
The Children's Hospital at Westmead, Sydney, Australia

<sup>5</sup>Centre for Transplant and Renal Research, Westmead Institute for Medical Research, The  
University of Sydney; Department of Renal Medicine, Westmead Hospital, Western Sydney Local  
Health District, Sydney, Australia

<sup>6</sup>Academic Nephrology Unit, Department of Infection Immunity & Cardiovascular Disease,  
University of Sheffield, United Kingdom

<sup>7</sup>Department of Medicine, The University of Chicago, United States;

<sup>8</sup>Division of Nephrology, Seoul National University Hospital, South Korea;

<sup>9</sup>Polycystic Kidney Disease Foundation of Australia, Australia;

<sup>10</sup>School of Medicine, Fu Jen Catholic University; Department of Internal Medicine, National Taiwan University Hospital, Taiwan;

<sup>11</sup>Kidney Health Initiative, Patient Family Partnership Council; President, The Voice of the Patient, United States

<sup>12</sup>Faculty of Medical Sciences, University Medical Center Gronigen, Netherlands;

<sup>13</sup>Division of Nephrology, Tufts Medical Center, Tufts University School of Medicine, United States;

<sup>14</sup>Polycystic Kidney Disease International, United Kingdom;

<sup>15</sup>Department of Nephrology and Hypertension, Mayo Clinic, United States;

<sup>16</sup>Division of Nephrology and Division of Genomic Medicine, University of Toronto, Canada;

<sup>17</sup>College of Medicine and Public Health, Flinders University, Adelaide, Australia

### **Corresponding author**

Bénédicte Sautenet

Service de Néphrologie-Hypertension, Dialyses, Transplantation Rénale, Hôpital de Tours, 2 boulevard Tonnellé, 37000 Tours, France

Tel: +33 2 3437 9674 Fax: +33 2 34378901

Email: benedicte.sautenet@univ-tours.fr

**Word count (abstract):** 378 words

**Word count (body):** 2270 words

## **Abstract**

**Rationale & objective:** Trials in autosomal dominant polycystic kidney disease (ADPKD) have increased, but their impact on decision-making has been limited. Since heterogeneity in reported outcomes may be responsible, we assessed their range and variability in ADPKD trials.

**Study Design:** Systematic review.

**Setting and Study Population:** Adult participants in clinical trials in ADPKD.

**Selection Criteria for Studies:** We included trials that studied adults and were published in English. For trials that enrolled patients without ADPKD, only those enrolling  $\geq 50\%$  of participants with ADPKD were included.

**Data extraction:** We extracted information on all discrete outcome measures, grouped them into 97 domains, and classified them into clinical, surrogate, and patient-reported categories. For each category, we choose 3 most frequently reported domains and performed a detailed analysis of outcome measures.

**Analytical approach:** Frequencies and characteristics of outcome measures were described.

**Results:** Among 68 trials, 1413 different outcomes measures were reported. Ninety-seven domains were identified, 41 (42%) were surrogate, 30 (31%) clinical, and 26 (27%) patient-reported. The 3 most frequently reported domains were in the surrogate category: kidney function (54; 79% of trials; using 46 measures), kidney and cyst volumes (43; 63% of trials; 52 measures), blood pressure (27; 40% of trials, 30 measures); in clinical category: infection (10; 15%; 21 measures), cardiovascular events (9; 13%; 6 measures), kidney failure requiring kidney replacement therapy (8; 12%; 5 measures); in the patient-reported category: pain related to ADPKD (16; 24%; 26 measures), pain for other reasons (11; 16%; 11 measures), diarrhea/constipation/gas (10; 15%; 9 measures).

**Limitations:** Outcomes measures were assessed for only the top 3 domains in each category.

**Conclusions:** The outcomes in ADPKD trials are broad in scope and highly variable. Surrogate outcomes were most frequently reported. Patient-reported outcomes were uncommon. A consensus-based set of core outcomes meaningful to patients and clinicians is needed for future ADPKD trials.

**Key words:** Autosomal dominant polycystic kidney disease (ADPKD), systematic review, outcomes, nephrology, epidemiology, trial design, surrogate end point, hard outcome, patient-reported outcome (PRO), kidney function, end-stage kidney disease (ESKD), kidney volume, cyst volume, blood pressure, pain, cardiovascular events, infection, patient-centered research, outcome heterogeneity.

## **Introduction**

Autosomal dominant polycystic kidney disease (ADPKD) is the leading cause of genetic kidney disease, which can be life-threatening<sup>1</sup>. Patients with ADPKD face a progressive disease course that often culminates in kidney failure, which necessitates dialysis or kidney transplantation. Approximately 70% of patients with ADPKD require kidney replacement therapy (KRT) by the age of 65 years<sup>2</sup>. ADPKD and its related complications including, cardiovascular, hepatic, digestive and neurological disease, and symptoms such as pain can severely impair psychosocial well-being and lifestyle<sup>3</sup>.

The past two decades have seen an increase in the number of randomized trials in patients with ADPKD. Since patients with ADPKD can experience a lengthy natural history of disease, the choice of outcomes in trials is challenging. Some events, such as the need for KRT, are unlikely to occur during the standard follow up time of a clinical trial. Therefore, trials in ADPKD have often focused on surrogate outcomes such as kidney volume and function<sup>6-9</sup>.

Systematic reviews of pharmacological interventions in patients on ADPKD confirm absence of clinical outcomes like kidney failure from many trial reports and demonstrate insufficient reporting on patient-reported outcomes such as pain<sup>10</sup>. Inconsistent reporting of outcomes of direct importance to patients and clinicians can limit decision-making and the ability to make reliable estimates of effect of interventions across trials.<sup>4,5</sup>

Detailed empiric evidence of outcome reporting in trials is not available in the context of ADPKD. The aim of this study was to assess the range and variability of outcome domains and measures reported in trials in ADPKD. This will inform the development of core outcomes sets that are important to patients with ADPKD, their families, and clinicians, for more consistent reporting of relevant outcomes to support decision-making.

## **Methods**

### *Selection criteria*

We searched MEDLINE, Embase, the Cochrane Kidney and Transplant Specialized Register, Australian and New Zealand Clinical Trials Registry (ANZCTR; [www.anzctr.org.au](http://www.anzctr.org.au)), the European clinical trials register ([www.clinicaltrialsregister.eu](http://www.clinicaltrialsregister.eu)) and ClinicalTrials.gov to identify all randomized controlled trials (RCT) and protocols of RCT involving patients with ADPKD, up to 1 October 2019 (the search strategy is available in **Table S1**). We excluded trials that did not include adults (aged 18 years or over), and those published in languages other than English. For trials that also enrolled patients without ADPKD, only trials with at least 50% of patients with ADPKD were included.

#### *Data extraction*

For each trial, we extracted the following trial characteristics: first author, year of publication, participating countries, sample size, mean age of participants, study duration, intervention type, primary outcome, and all discrete outcome measures. A discrete outcome measure was defined as any measurement or event reported separately for all trial arms. All levels of specification of the outcome measures were extracted if reported, domain (e.g. kidney function), specific measurement (e.g. estimation of glomerular filtration rate [eGFR] by the Modification of Diet in Renal Disease [MDRD] equation), method of aggregation (percentage change), specific metric (between the start and the end of the study period), and time point of measure from trial commencement<sup>15,16</sup>.

#### *Analysis*

The discrete outcome measures from all included trials were classified into outcome domains by one reviewer (BS). The list of outcome domains was reviewed by two reviewers independently (AT and YC) and any discrepancies were discussed to reach agreement about the classification (AT, BS and YC). These outcome domains were further grouped into three categories: surrogate (biochemical or physiological outcomes that may or may not be validated as a substitute for a clinical outcome; e.g., hemoglobin), clinical (medical event or comorbidity diagnosed by the clinician; e.g., cardiovascular disease), and patient-reported (outcomes reported

directly by patients regarding how they feel or function), using standard definitions<sup>17-21</sup>. The classification was determined by the same three authors. The number of trials that reported each outcome domain was calculated. For each category (clinical, patient reported and surrogate outcome domain), we chose the three most frequently reported outcome domains and performed a detailed analysis of outcome measures to explore their heterogeneity. We performed descriptive analyses using R version 3.2.3 (R Foundation for Statistical Computing, Vienna, Austria, URL <http://www.R-project.org/>)

## **Results**

### *Trial characteristics*

We identified and included 68 trials involving 10750 participants (**Figure 1**). Thirty-six (53%) trials were published, one (1%) was a protocol, and 31 (46%) were registered trials that were unpublished. The year of publication/registration ranged from 2001 to 2019. The median duration of trials was 18 (interquartile range [IQR], 6-24) months. The median sample size of trials were 50 (IQR, 29-100) participants. Fifty-nine (86%) trials assessed a pharmacological intervention, three (5%) evaluated a surgical intervention, and six (9%) assessed a dietary intervention. The trial characteristics are provided in **Table 1**.

### *Outcome measures and domains*

Across the 68 trials, 1413 outcomes measures were reported. The median number of outcome measures (defined as a different measurement, aggregation, metric and time point) was 11 (IQR, 6-30) per trial. The median number of outcome measures exclusive of time points was 7 (IQR, 5-19) per trial. The 1413 outcome measures were classified into 97 outcome domains, of which 41 (42%) were surrogate, 30 (31%) were clinical, 26 (27%) were patient-reported outcomes. The top six most frequently reported outcome domains were kidney function (54; 79% of trials), kidney and cyst volumes (43; 63%), blood pressure (27; 42%), proteinuria and albuminuria (22; 32%), unspecified adverse events (20; 29%) and pain (kidney, abdominal, epigastric (16; 24%]). Ninety outcome domains (93%) were reported in less than 20% of trials. **Figure 2** shows the

proportion of trials reporting each outcome domain. Mortality and kidney failure requiring KRT were reported in 6 (9%) and 8 (12%) trials, respectively.

**Figure 3** presents the number of unique outcomes measures and time points for the top three outcome domains for each category (surrogate, clinical, patient-reported) of outcomes. The three most frequent surrogate outcomes were “kidney function” (54; 79% of trials), which had 46 outcome measures (131 including time points), “kidney and cyst volumes” (43; 63% trials) which had 52 (88 including time points) outcome measures, and “blood pressure” (28; 41% trials) which had 30 (65 including time points) outcome measures (**Figure 4A-C**). The specific measurement used for the three most frequent surrogate outcomes are detailed in **Table S2**. The three most frequently reported clinical outcomes were “infection” (10; 15% of trials), which had 21 (33 including time points) measures, “cardiovascular event” (9; 13% trials) which had 6 different outcome measures (14 including different time points), and “ESKD” (8; 12% of trials) which had 5 (17 including time points) outcome measures (**Figure 4D-F**). The three most frequent patient-reported outcomes were “pain (kidney, abdominal, epigastric)” (16; 24% of trials), which had 26 outcome measures (42 including time points), “pain (other)” (11; 16% of trials) which had 11 (18 including time points) outcome measures, and “diarrhea/constipation/gas/bloating (10; 15% of trials) which had 9 (16 including time points) outcome measures (**Figure 4G-I**). The specific tools used to measure pain are detailed in **Table S3**.

We performed a sensitivity analysis by category of outcome over time and assessed the proportion of trials that reported at least one outcome domain per category (clinical, patient reported and surrogate outcome domain) per time period. The results indicate a nominal trend of increasing frequency of clinical and patient reported outcomes, but this was not statistically significant (**Figure S1**).

#### *Characteristics of primary outcomes*

Across the 68 trials, a primary outcome was specified in 56 (82%) trials; 47 (69%) trials specified a single primary outcome; and 9 (13%) specified multiple primary outcomes. The 47

studies reporting a single primary outcome were primarily surrogate (45; 66% of trials) and much less commonly clinical (1; 2% of trials), and patient-reported outcomes (1; 2% of trials). Among the 47 single primary outcomes, the two most frequently reported were kidney and cyst volumes (17; 27% of trials) and kidney function (13; 19% of trials).

## **Discussion**

The outcomes reported in ADPKD trials are very broad in scope (97 outcome domains) and inconsistently reported across trials, with 93% of these outcome domains reported in less than 20% of trials. Most (73%) outcome domains were either surrogate or clinical outcomes. The most frequently reported outcome domains were surrogate endpoints such as kidney function, kidney and cyst volumes, blood pressure, and proteinuria/albuminuria. The most frequently reported clinical outcomes were infection, cardiovascular events, and kidney failure requiring KRT, which were reported in 16%, 14%, and 13% of trials, respectively. Mortality was reported in 9% of trials. Pain related to kidney cyst was the most frequently reported patient-reported outcome, and it appeared in 24% of trials. There was also a large range and variability at the level of outcome measures, with 1413 different outcome measures reported across trials.

Studies have shown that patients are concerned about the need for dialysis or kidney transplantation and this clinical outcome has been consistently identified to be of highest priority among patients with ADPKD and health professionals<sup>28-30</sup>. However, because ADPKD is a slowly progressive disease, trials with clinical endpoints in ADPKD may not be feasible. For example, the HALT-PKD trial had a follow up of up to 7 years, yet only 10% of the participants required KRT<sup>27</sup>. Not surprisingly, kidney failure requiring KRT has been reported in just 13% of trials in ADPKD.

Instead, trials in ADPKD frequently report the outcomes kidney function and kidney and cyst volumes<sup>7-9</sup>. Although recent updates made by the US Food and Drug Administration and European Medicines Agency<sup>22,23</sup> recognize assessment of kidney function with eGFR as an appropriate intermediate endpoint for CKD, and total kidney volume is qualified by the US Food and Drug Administration and the European Medicines Agency as a prognostic biomarker for

selecting patients at high risk for a progressive decline in kidney function<sup>24</sup>, the evidence to support the validity and applicability of these surrogate endpoints remain uncertain. We have shown that current outcome measures for kidney function and kidney volume reported in trials vary widely, with 38 measures for kidney function and 55 measures for kidney and cyst volumes. Such variability in outcome measures limits reliable estimates of the effects of interventions across trials. Indeed, we demonstrate that 95% (92/97) of the outcome domains were reported in less than 30% of trials. This finding shows the potential for serious outcome reporting bias in meta-analysis of trials in ADPKD<sup>37,38</sup>.

Patients with ADPKD experience very specific pains and troubles that are not found in other patients with CKD. Patients have described ADPKD as a “painful inheritance”<sup>31</sup> and the intense and unpredictable pain may be underrecognized by health professionals. Quality of life (QoL) is also known to be impaired in patients with ADPKD<sup>32</sup>, and a recent systematic review found that QoL was lower in patient with ADPKD compared to the general population and was not associated with kidney function and kidney volume<sup>33</sup>. Our findings show that patient-reported outcomes were infrequently reported across trials in ADPKD. Despite being the most frequently reported patient-reported outcome, pain appeared in only 16% of trials. Among other patient-reported outcomes reported in the ADPKD trials were side effects caused by the medications. Outcomes that have been highly prioritized by patients and caregivers with ADPKD include ability to work, mobility/physical function, and fatigue, which were reported in 2%, 9%, and 11% trials, respectively<sup>35</sup>.

The omission of patient-important outcomes in trials has also been noted in dialysis, kidney transplantation, and pediatric kidney disease<sup>11,12,36</sup>. This may be explained by the lack of patient-reported outcome measures (PROMs) that have been validated in this population. There are efforts to develop tools to measure and report patient-reported outcomes, such as the ADPKD Impact Scale (ADPKD-IS)<sup>34</sup>, which was developed with input from patients and clinicians. The ADPKD-IS addresses three conceptual domains: physical, emotional and fatigue, and health-related QoL and

specific disease burden in ADPKD patients. It is important to obtain a consensus on which patient-reported outcome matter to all stakeholders in order to validate a specific measure in ADPKD trials. We suggest that further work is needed to establish feasible and validated PROMs to support consistent assessment and reporting of symptoms and life impact outcomes across trials.

This study provides detailed evidence of the heterogeneity of outcomes reported in trials in people with ADPKD. However, there are potential limitations. We only assessed outcomes reported in trials and could not ascertain outcomes that were actually measured, recognizing that some outcomes may have been measured but not reported in the trial. Non-English trials were excluded, so we could have underestimated the range and heterogeneity of outcomes. We did not analyze all the measures reported because of resource constraints and because additional evidence of further heterogeneity was unlikely to be more informative; instead we analyzed the outcomes measures for the top three most frequently reported outcomes domains for each category (surrogate, clinical, and patient-reported).

These results highlight the need for consensus on critically important outcomes to be measured and reported consistently in all trials involving patients with ADPKD, to ensure that trials address the shared priorities of patients, caregivers, and health professionals, and thereby support better care and outcomes in ADPKD. As part of the global Standardized Outcome in Nephrology (SONG) initiative<sup>14</sup>, SONG-PKD was recently launched to establish core outcomes with the involvement of patients, caregivers and health professionals.

The outcomes reported in ADPKD trials are varied, heterogeneous, and focused on surrogate outcomes related to progression to kidney failure requiring KRT. Clinical and patient-reported outcomes such as KRT requirement and pain are seldom reported. The development of a core outcome set for ADPKD will improve outcome reporting, which will be of relevance and of importance to all stakeholders in clinical trials, and ultimately will strengthen trial-based evidence to inform decision-making in ADPKD based upon the outcomes that matter to patients, caregivers and health professionals.

## **Supplementary Material**

Figure S1: Difference in the proportion of trials that reported at least 1 clinical, patient-reported, and surrogate outcome over time.

Table S1: Search strategy.

Table S2. Specific measurements used for kidney function, kidney and cyst volume, and blood pressure.

Table S3. Specific questionnaire used for pain.

Supplementary Material Descriptive Text for Online Delivery  
Supplementary File (PDF). Figure S1; Tables S1-S3.

## **Article information**

SONG-PKD Initiative Members: Gopala Rangan, Albert Ong, Arlene Chapman, Curie Ahn, Helen Coolican, Juliana Tze-Wah Kao, Kevin Fowler, Ron Gansevoort, Ronald Perrone, Tess Harris, Vicente Torres, York Pei, Yeoungjee Cho, Talia Gutman, Benedicte Sautenet.

Authors' Full Names and Academic Degrees:

Authors' Affiliations:

Address for Correspondence:

Authors' Contributions: Research design: all authors; Data collection: BS, YC, JCC, AT; Data analysis: all authors. Each author contributed important intellectual content during manuscript drafting or revision and agrees to be personally accountable for the individual's own contributions and to ensure that questions pertaining to the accuracy or integrity of any portion of the work, even one in which the author was not directly involved, are appropriately investigated and resolved, including with documentation in the literature if appropriate.

Support: The project is funded by the National Health and Medical Research Council (NHMRC) Better Evidence and Translation (BEAT-CKD) Program Grant (APP1092957). AT is

supported by a NHMRC Career Development Fellowship (APP1106716). YC is supported by a NHMRC Early Career Fellowship (APP1126256). The funders had no role in study design, data collection, analysis, reporting or to the decision to submit the publication.

**Financial Disclosure:** The authors declare that they have no relevant financial interests.

**Prior Presentation:** Aspects of this work were presented in abstract form at the ISN World Congress of Nephrology, held in Melbourne, Australia, 12 April 2019 - 15 April 2019.

**Peer Review:** Received \_\_\_\_\_. Evaluated by 2 external peer reviewers, with direct editorial input from a Statistics/Methods Editor, an Associate Editor, and the Editor-in-Chief.

Accepted in revised form December 16, 2019.

## **References**

1. Gabow PA. Autosomal dominant polycystic kidney disease. *N Engl J Med.* 1993 Jul 29;329(5):332-42.
2. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. *Kidney Int.* 2009;76(2):149–68.
3. Miskulin DC, Abebe KZ, Chapman AB, et al. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study. *Am J Kidney Dis.* 2014 Feb;63(2):214-26.
4. Myint TM, Rangan GK, Webster AC. Treatments to slow progression of autosomal dominant polycystic kidney disease: systematic review and meta-analysis of randomized trials. *Nephrology (Carlton).* 2014 Apr;19(4):217-26.
5. Cho Y, Sautenet B, Rangan G, et al. Standardised Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease. *Trials.* 2017 Nov 23;18(1):560. doi: 10.1186/s13063-017-2298-4.

6. Caroli A, Perico N, Perna A, et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. *Lancet*. 2013 Nov 2;382(9903):1485-95.
7. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. *N Engl J Med*. 2012 Dec 20;367(25):2407-18.
8. Torres VE, Abebe KZ, Chapman AB, et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease. *N Engl J Med*. 2014 Dec 11;371(24):2267-76.
9. Seliger SL1, Abebe KZ2, Hallows KR3, et al. A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease. *Am J Nephrol*. 2018;47(5):352-360.
10. Bolognani D, Palmer SC, Ruospo M, Zoccali C, Craig JC, Strippoli GF. Interventions for preventing the progression of autosomal dominant polycystic kidney disease. *Cochrane Database Syst Rev*. 2015 Jul 14;(7):CD010294.
11. Sautenet B, Tong A, Williams G, et al. Scope and Consistency of Outcomes Reported in Randomized Trials Conducted in Adults Receiving Hemodialysis: A Systematic Review. *Am J Kidney Dis*. 2018 Jul;72(1):62-74.
12. Sautenet B, Tong A, Chapman JR, et al. Range and Consistency of Outcomes Reported in Randomized Trials Conducted in Kidney Transplant Recipients: A Systematic Review. *Transplantation*. 2018 Dec;102(12):2065-2071.
13. Williamson PR, Altman D, Blazeby JM, Clarke M, Devane D, Gargon E, Tugwell P. Developing core outcome sets for clinical trials: issues to consider. *Trials*. 2012;13:132.
14. Tong A, Manns B, Wang AYM, et al. Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop. *Kidney Int*. 2018 Dec;94(6):1053-1068.
15. Zarin DA1, Tse T, Williams RJ, et al. The ClinicalTrials.gov results database--update and key issues. *N Engl J Med*. 2011 Mar 3;364(9):852-60.

16. Sautenet B, Caille A, Halimi JM, et al. Better reporting and greater homogeneity in outcome measures are seen in randomized trial protocols when guidelines exist. *J ClinEpidemiol*. 2013 Aug;66(8):838-46.
17. Black N. Patient reported outcome measures could help transform healthcare. *BMJ*. 2013;346:f167.
18. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? *Ann Intern Med*. 1996;125:605–613.
19. FDA. Surrogate Endpoint Resources for Drug and Biologic Development. Available at <https://www.fda.gov/drugs/development-resources/surrogate-endpoint-resources-drug-and-biologic-development>. Page Last Updated: 07/24/2018.
20. Basch E, Torda P, Adams K. Standards for patient-reported outcomebased performance measures. *JAMA*. 2013;310:139–140.
21. Svensson S, Menkes DB, Lexchin J. Surrogate outcomes in clinical trials: a cautionary tale. *JAMA Intern Med*. 2013;173:611–612.
22. Levey AS, Inker LA, Matsushita K, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. *Am J Kidney Dis*. 2014 Dec;64(6):821-35.
23. Levey AS, Gansevoort RT, Coresh J, et al. Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. *Am J Kidney Dis*. 2020 Jan;75(1):84-104.
24. Perrone RD, Mouksassi MS, Romero K, et al. Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease. *Kidney Int Rep*. 2017 Jan 16;2(3):442-450.
25. Irazabal MV, Torres VE. Total Kidney Volume and Autosomal Dominant Polycystic Kidney Disease: A Long-Standing Relationship. *Am J Nephrol*. 2018;48(1):65-66.

26. Smith KA, Thompson AM, Baron DA, Broadbent ST, Lundstrom GH, Perrone RD. Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC). *Am J Kidney Dis*. 2019 Apr;73(4):533-541.
27. Torres VE, Abebe KZ, Chapman AB, et al. Angiotensin Blockade in Late Autosomal Dominant Polycystic Kidney Disease. *N Engl J Med*. 2014;371(24):2267–2276.
28. Cho Y, Sautenet B, Gutman T, et al. Identifying patient-important outcomes in polycystic kidney disease: An international nominal group technique study. *Nephrology (Carlton)*. 2019 Jan 20.
29. Evangelidis N, Tong A, Manns B, et al. Developing a set of core outcomes for trials in hemodialysis: an international Delphi survey. *American Journal of Kidney Disease* 2017;70(4):464-475.
30. Sautenet B, Tong A, Manera KE, et al. Developing consensus-based priority outcome domains for trials in kidney transplantation: a multinational Delphi survey with patients, caregivers and health professionals. *Transplantation* 2017; 101:1875-1886.
31. Tong A, Rangan GK, Ruospo M, et al. A painful inheritance-patient perspectives on living with polycystic kidney disease: thematic synthesis of qualitative research. *Nephrol Dial Transplant*. 2015 May;30(5):790-800. doi: 10.1093/ndt/gfv010. Epub 2015 Jan
32. Eriksson D, Karlsson L, Eklund O, et al. Health-related quality of life across all stages of autosomal dominant polycystic kidney disease. *Nephrol Dial Transplant*. 2017 Dec 1;32(12):2106-2111.
33. Neijenhuis MK, Kievit W, Perrone RD, et al. The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression. *BMC Nephrol*. 2017 May 25;18(1):169.
34. Oberdhan D, Cole JC, Krasa HB, et al. *Am J Kidney Dis*. 2018 Feb;71(2):225-235.  
Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument.

35. Cho Y, Sautenet B, Gutman T et al. Identifying patient-important outcomes in polycystic kidney disease: An international nominal group technique study. *Nephrology* 2019 Jan 20. doi: 10.1111/nep.13566.
36. Chong LSH, Sautenet B, Tong A, et al. Range and Heterogeneity of Outcomes in Randomized Trials of Pediatric Chronic Kidney Disease. *J Pediatr*. 2017 Jul;186:110-117.e11.
37. Schmid CH. Outcome Reporting Bias: A Pervasive Problem in Published Meta-analyses. *Am J Kidney Dis*. 2017 Feb;69(2):172-174.
38. Kirkham JJ, Altman DG, Chan AW, Gamble C, Dwan KM, Williamson PR. Outcome reporting bias in trials: a methodological approach for assessment and adjustment in systematic reviews. *BMJ*. 2018 Sep 28;362:k3802.

**Table 1. Characteristics of included trials (n=68)**


<b>Trial characteristic</b>	<b>No. (%) of trials</b>
<b>Year of publication</b>	
2001-2005	6 (9)
2006-2010	18 (26)
2011-2015	19 (28)
2016-2019	25 (37)
<b>Duration of trial</b>	
< 6 mo	10 (15)
6 – 11 mo	8 (12)
12 – 23 mo	16 (23)
24 – 35 mo	20 (29)
≥ 36 mo	14 (21)
<b>Sample size</b>	
1 to 50 participants	32 (47)
51 to 100 participants	16 (24)
101 to 200 participants	9 (13)
>200 participants	11 (16)
<b>Location</b>	
United States of America	23 (34)
Europe	27 (40)
Asia	11 (16)
Oceania	2 (3)
Multinational studies	5 (7)
<b>Intervention type</b>	
Pharmacological	59 (87)
Dietary	6 (9)
Surgical	3 (4)

**Figure 1. Search results**


**Figure 2. Frequency of outcomes domains reported in trials in autosomal dominant polycystic kidney disease. Proportions are expressed in a x10 log scale to display proportion <1%**

**Figure 3. Number of outcome measures and time points used for selected outcome domains.**

**Figure 4a-i. Outcome measures and time points reported for selected outcome domains.**



# Outcomes domains (n=97)



**Categories of outcome:**

- Surrogate (n=41)
- Clinical (n=30)
- Patient reported (n=26)

